BRPI1012240A2 - derivados de 5-beta, beta-14-androstana úteis para o tratamento de proteinúria, de glomeruloesclerose e de insuficiência renal - Google Patents

derivados de 5-beta, beta-14-androstana úteis para o tratamento de proteinúria, de glomeruloesclerose e de insuficiência renal

Info

Publication number
BRPI1012240A2
BRPI1012240A2 BRPI1012240A BRPI1012240A BRPI1012240A2 BR PI1012240 A2 BRPI1012240 A2 BR PI1012240A2 BR PI1012240 A BRPI1012240 A BR PI1012240A BR PI1012240 A BRPI1012240 A BR PI1012240A BR PI1012240 A2 BRPI1012240 A2 BR PI1012240A2
Authority
BR
Brazil
Prior art keywords
beta
glomerulosclerosis
proteinuria
treatment
renal failure
Prior art date
Application number
BRPI1012240A
Other languages
English (en)
Inventor
Ferrari Patrizia
Bianchi Giuseppe
Ferrandi Mara
Original Assignee
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Publication of BRPI1012240A2 publication Critical patent/BRPI1012240A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0038—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an androstane skeleton, including 18- or 19-substituted derivatives, 18-nor derivatives and also derivatives where position 17-beta is substituted by a carbon atom not directly bonded to a further carbon atom and not being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI1012240A 2009-03-23 2010-03-18 derivados de 5-beta, beta-14-androstana úteis para o tratamento de proteinúria, de glomeruloesclerose e de insuficiência renal BRPI1012240A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09155834 2009-03-23
PCT/EP2010/053571 WO2010108855A1 (en) 2009-03-23 2010-03-18 5-β, 14-β-ANDROSTANE DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEINURIA, GLOMERULOSCLEROSIS AND RENAL FAILURE

Publications (1)

Publication Number Publication Date
BRPI1012240A2 true BRPI1012240A2 (pt) 2018-06-12

Family

ID=40622086

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1012240A BRPI1012240A2 (pt) 2009-03-23 2010-03-18 derivados de 5-beta, beta-14-androstana úteis para o tratamento de proteinúria, de glomeruloesclerose e de insuficiência renal

Country Status (21)

Country Link
US (2) US20120028945A1 (pt)
EP (1) EP2411015B1 (pt)
JP (1) JP5738267B2 (pt)
KR (1) KR101656797B1 (pt)
CN (1) CN102361643B (pt)
AU (1) AU2010227644B2 (pt)
BR (1) BRPI1012240A2 (pt)
CA (1) CA2754642C (pt)
DK (1) DK2411015T3 (pt)
EA (1) EA019929B1 (pt)
ES (1) ES2559005T3 (pt)
HU (1) HUE027408T2 (pt)
IL (1) IL214477A (pt)
MX (1) MX2011009321A (pt)
NZ (1) NZ594412A (pt)
PL (1) PL2411015T3 (pt)
PT (1) PT2411015E (pt)
SG (2) SG2014010912A (pt)
UA (1) UA103664C2 (pt)
WO (1) WO2010108855A1 (pt)
ZA (1) ZA201107647B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME02347B (me) * 2009-10-19 2016-06-20 Rostaquo S P A Rostafuroksin za farmakogenomsko lečenje kardiovaskularnih stanja
CN102940640A (zh) * 2012-12-06 2013-02-27 中国生命药物治疗有限公司 罗他夫辛在制备治疗基因缺陷型原发性高血压的药物中的用途
CN105078954A (zh) * 2015-08-20 2015-11-25 南京华宽信息咨询中心 一种治疗急性肾衰药物及其应用
CN108152432B (zh) * 2017-12-29 2020-11-20 兆科药业（合肥）有限公司 一种罗他夫辛片高效液相检测方法
US11337988B2 (en) 2018-09-27 2022-05-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of ouabain antagonists to inhibit viral infection
DK3805243T3 (da) * 2019-10-09 2024-01-02 Windtree Therapeutics Inc Androstanderivater med aktivitet som rene eller hovedsageligt rene stimulatorer af serca2a til behandling af hjertesvigt

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4227616C2 (de) * 1992-08-20 1995-04-13 Sigma Tau Ind Farmaceuti 17-(3-Furyl)-und 17-(4-Pyridazinyl)-5beta, 14beta-androstanderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammemsetzungen
DE4232638C2 (de) 1992-09-29 1994-11-17 Sigma Tau Ind Farmaceuti 17-Phenyl-5beta-14beta-androstanderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
DE4232681C2 (de) 1992-09-29 1994-11-24 Sigma Tau Ind Farmaceuti 17-Phenyl- und 17-Furyl-14beta,5alpha-androstan- und androsten- Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung
TWI389917B (zh) * 2006-04-13 2013-03-21 Sigma Tau Ind Farmaceuti 作為心血管疾病治療藥物的雄甾烷與雄甾烯之氮雜環烷基衍生物
TWI392682B (zh) * 2006-04-13 2013-04-11 Sigma Tau Ind Farmaceuti 作為心血管疾病的治療藥物之雄甾烷和雄甾烯的胺基衍生物
TWI372762B (en) * 2006-06-23 2012-09-21 Sigma Tau Ind Farmaceuti Amino derivatives of b-homoandrostanes and b-heteroandrostanes
CA2688079C (en) * 2007-06-07 2016-05-03 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. 5beta, 14beta-androstane derivatives useful for the treatment of restenosis after angioplastic or endoartherectomy and diseases due to organ fibrosis

Also Published As

Publication number Publication date
HUE027408T2 (en) 2016-10-28
EA201171155A1 (ru) 2012-03-30
US20120028945A1 (en) 2012-02-02
PL2411015T3 (pl) 2016-05-31
SG2014010912A (en) 2014-06-27
CA2754642A1 (en) 2010-09-30
KR101656797B1 (ko) 2016-09-12
WO2010108855A1 (en) 2010-09-30
NZ594412A (en) 2013-10-25
JP5738267B2 (ja) 2015-06-24
EA019929B1 (ru) 2014-07-30
IL214477A (en) 2017-04-30
ZA201107647B (en) 2012-07-25
US9868757B2 (en) 2018-01-16
AU2010227644A1 (en) 2011-09-01
KR20110133027A (ko) 2011-12-09
EP2411015B1 (en) 2015-12-23
CN102361643B (zh) 2016-05-18
ES2559005T3 (es) 2016-02-10
AU2010227644B2 (en) 2016-05-19
SG174260A1 (en) 2011-10-28
US20160251392A1 (en) 2016-09-01
IL214477A0 (en) 2011-09-27
JP2012521383A (ja) 2012-09-13
MX2011009321A (es) 2011-10-03
EP2411015A1 (en) 2012-02-01
PT2411015E (pt) 2016-02-26
UA103664C2 (ru) 2013-11-11
CA2754642C (en) 2016-11-08
DK2411015T3 (en) 2016-02-08
CN102361643A (zh) 2012-02-22

Similar Documents

Publication Publication Date Title
DK2808024T3 (da) Bifidobakterier til behandling af kongestiv hjerteinsufficiens
BRPI1015569A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias.
DK2151833T3 (da) Transformersystem
ATE526024T1 (de) Fluvoxamin vermeidende pirfenidontheraphy
FI20125961A (fi) Menetelmä myllyn käytöksi
BR112012003372A2 (pt) vitamina d3 e análogos da mesma para o tratamento de alopecia.
BR112012000434A2 (pt) procedimento para a fabricação de piscinas naturais.
ZA201001264B (en) 1-amino-alkylcycohxane derivatives for the treatment of cochleat tinnitus
DK2442870T3 (da) Pyrazinooxazepin-derivater.
BRPI0906606A2 (pt) Tratamento terapêutico para condições do pulmão.
BRPI1012240A2 (pt) derivados de 5-beta, beta-14-androstana úteis para o tratamento de proteinúria, de glomeruloesclerose e de insuficiência renal
FI20070986A (fi) Kuljetusjärjestelmän tehonohjaus
FI20070489A (fi) Kuljetusjärjestelmän tehonohjaus
FI20100225A0 (fi) Bassokaiuttimen rakenne ja menetelmä bassokaiuttimen säätämiseksi
BR112012002267A2 (pt) compostos para o tratamento de inflamação.
BR112012004258A2 (pt) "método com tetraarilborato para fabricação de bifenilos substituintes"
BRPI1009435A2 (pt) tratamento para câncer no pâncreas
FR2946246B1 (fr) Fauteuil roulant.
BRPI0812105A2 (pt) Neramexano para o tratamento de nistagmo
ES1071762Y (es) Soporte para reglas de albañileria
ES1070176Y (es) Soporte para tableros, paneles o similares
FI20095850A0 (fi) Rakennelma ja menetelmä rakennelman valmistamiseksi, sekä rakennelman käyttö
BRPI1011268A2 (pt) tubulação, e, método para a fabricação de uma tubulação.
BR112012000952A2 (pt) método de exo-s-mecamilamina, uso, e composto para tratamento
BRPI0923903A2 (pt) Derivados de piridazinona

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: CVIE THERAPEUTICS LIMITED (TW)

B25A Requested transfer of rights approved

Owner name: CVIE THERAPEUTICS LIMITED (TW)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL

B350 Update of information on the portal [chapter 15.35 patent gazette]